Public-private partnership launched a first-of-its-kind phase 2b/c trial to evaluate two novel tuberculosis drug regimens with the potential to treat all forms of active pulmonary TB

-- TB preventive treatment could slash deaths rate by 35 per cent
-- Children under five could be biggest beneficiary
-- The preventive treatment will be a cost-effective solution for high-incidence countries

Political commitment will be key to eliminating TB as a public health challenge, says Austin Arinze Obiefuna (vice chair of the Stop TB Partnership and executive director of Afro Global Alliance) in an opinion published in The BMJ.

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world's deadliest infectious disease. Mtb is so successful and harmful because it can adapt to different conditions inside our bodies, allowing it to evade treatment.

RESIST-TB released its August 2023 newsletter with the latest updates and research publications on drug-resistant TB.

The International Union Against Tuberculosis and Lung Disease (The Union) provided information related to the latest updates to one of its free online courses - Child and adolescent TB training course for healthcare workers.

Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.

A toolkit, developed by Treatment Action Group, is designed to facilitate community participation in the development and review of clinical trials protocols.

The Stop TB Partnership provided the latest information related to the participation in the United Nations High-Level Meeting (HLM) on TB on 22 September 2023.

31 July 2023  | Geneva-- To inform research and development priorities for tuberculosis (TB) diagnostics and address unmet needs, the World Health Organization (WHO) is in the process of updating high-priority target product profiles (TPPs) for TB diagnostics. TPPs provide detailed technical specifications that are important to end-users (e.g. a test’s required performance) and operational characteristics to inform product manufacturers. Due to continuous developments in a TB diagnostic and treatment domains, there is ongoing need to regularly update TPPs in order to adapt them to an evolving context of a global TB control needs. Current update focuses on the TB diagnostic tests for peripheral settings.